JY-016

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameJY-016
Drug Alias NameJY-016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Epidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursLung NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Jingyitaixiang Technology Development Co LtdBeijing Eastern Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBiotech Pharmaceutical Co LtdBeijing Jingyitaixiang Technology Development Co LtdBeijing Eastern Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A